Subscribe
stockstudio-shutterstock-com
StockStudio / Shutterstock.com
10 September 2020Big PharmaSarah Morgan

EU concludes COVID-19 vaccine talks with Pfizer

The European Commission has concluded exploratory talks with Pfizer and BioNTech to potentially supply 300 million doses of their investigational vaccine against COVID-19.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
EC signs contract with Pfizer to access watershed vaccine
12 November 2020   The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.
Big Pharma
Counterfeiters ‘exploiting demand’ for COVID-19 vaccines
27 April 2021   Pfizer has discovered counterfeit versions of its COVID-19 vaccine in Mexico and Poland, prompting governments to reassure the public over the safety of vaccine supply chains.
Europe
EU backs compulsory licensing for COVID vaccines
8 June 2021   The European Union has submitted a new proposal to the World Trade Organisation, which backs compulsory licensing agreements for COVID-19 vaccines when negotiations fail.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
EC signs contract with Pfizer to access watershed vaccine
12 November 2020   The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.
Big Pharma
Counterfeiters ‘exploiting demand’ for COVID-19 vaccines
27 April 2021   Pfizer has discovered counterfeit versions of its COVID-19 vaccine in Mexico and Poland, prompting governments to reassure the public over the safety of vaccine supply chains.
Europe
EU backs compulsory licensing for COVID vaccines
8 June 2021   The European Union has submitted a new proposal to the World Trade Organisation, which backs compulsory licensing agreements for COVID-19 vaccines when negotiations fail.

More on this story

Big Pharma
EC signs contract with Pfizer to access watershed vaccine
12 November 2020   The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.
Big Pharma
Counterfeiters ‘exploiting demand’ for COVID-19 vaccines
27 April 2021   Pfizer has discovered counterfeit versions of its COVID-19 vaccine in Mexico and Poland, prompting governments to reassure the public over the safety of vaccine supply chains.
Europe
EU backs compulsory licensing for COVID vaccines
8 June 2021   The European Union has submitted a new proposal to the World Trade Organisation, which backs compulsory licensing agreements for COVID-19 vaccines when negotiations fail.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York